Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Catalyst falls after CPP-109 miss

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) fell $1.20 (57%) to $0.90 on Friday after top-line data from

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE